期刊文献+

国内外疫苗使用说明书规范的比较和探讨 被引量:3

Comparison and discussion of domestic and overseas vaccine package insert criteria
原文传递
导出
摘要 目的了解国外疫苗使用说明书的规范要求和现行国外说明书的优点和经验,为完善规范我国的疫苗说明书提供参考。方法对美国、欧盟和我国疫苗使用说明书的制定规范、格式和主要内容进行比较。结果美国、欧盟和我国疫苗使用说明书的格式较为接近,而在制定规范以及药理学、毒理学、临床试验和不良反应等主要内容方面存在较大差异。结论我国应该借鉴国外药品监管当局对于说明书的规范要求,完善说明书的制定规范,细化说明书的信息,扩大疫苗信息知晓度,以保障疫苗的安全性和有效性。 Objective To learn overseas vaccine package insert criteria and advantages and experience of current package inserts, and to enhance standardization of package inserts in our country. Methods The criteria, formats and main contents of the vaccine package inserts in the USA and European Union (EU) were compared with those in China. Results The formats in the USA, EU and China were similar, but the criteria and main contents, including pharmacology, toxicology, clinical trials, and adverse reactions, were different from each other greatly. Conclusions The contents and criteria established by overseas regulatory authorities should be used for reference. The safety and effectiveness of vaccines would be guaranteed by detailing and perfecting package insert criteria and strengthening legislation.
作者 马雷钧
出处 《国际生物制品学杂志》 CAS 2011年第5期246-251,共6页 International Journal of Biologicals
关键词 疫苗使用说明书 内容 格式 规范化 Vaccine package insert Content Format Standardization
  • 相关文献

参考文献10

  • 1国家食品药品监督管理局.关于印发化学药品和生物制品说明书规范细则的通知[S].2006.5.
  • 2European Commission Enterprise and Industry Directorate- General. A guideline on summary of product characteristics [S]. 2009- 09.
  • 3Food and Drug Administration. 21 CFR Parts 201, 314, and 601. Requirements on content and format of labeling for human prescription drug and biological products and draft guidances and two guidances for industry on the content and format of labeling for human prescription drug and biological products; Final rule and notices [ S] 2006-01-9.4.
  • 4U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Clinical pharmacology section of labeling for human prescription drug and biological products--content and format (draft zuidance) [S]. 2009-02.
  • 5U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Clinical studies section of labeling for human prescription drug and biological products--content and format [S]. 2006-01.
  • 6U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Adverse reactions section of labeling for human prescription drug and biological products--content and format (draft guidance) [S]. 2006-01.
  • 7U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research ( CBER ). Warnings and precautions, eontraindications, and boxed, warning sections of labeling for human prescription drug and biological products--content and format (draft guidance ) [ S]. 2006-01.
  • 8U.S. Department of Health and Haman Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Labeling for human prescription drug and biological products--implementing the new content and format requirements (draft auidance)[S]. 2006-01.
  • 9国家食品药品监督管理局.预防用疫苗临床前研究技术指导原则[S].2005-10-14.
  • 10国家食品药品监督管理局.药品注册管理办法[S].北京:2007.

共引文献34

同被引文献36

引证文献3

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部